Barclays analyst Emily Field upgraded Sanofi to Overweight from Equal Weight with a price target of EUR 115, up from EUR 90. The analyst thinks Sanofi’s improving earnings trajectory, bolstered by Dupixent’s chronic obstructive pulmonary disease data, makes it the "value" name of choice for fiscal 2023. "In this market, defense wins championships," writes the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- Sanofi Gains after Dupxient Shows Promise in COPD
- Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints
- Regeneron, Sanofi announce EC approval of Dupixent
- Regeneron, Sanofi present results from Dupixent clinical trial
- Sanofi says moderate-to-severe atopic hand, foot dermatitis trial met endpoints